Europe steps in to protect discounted drugs for developing countries
1 December 2002. Related: Treatment access.
2002
Protecting mothers from mono and dual therapies, and considering the value of Caesarean sections
1 December 2002. Related: Meeting report.
Boosted PIs: differences emerging in efficacy, tolerability, lipids
1 December 2002. Related: Antiretrovirals.
Europe steps in to protect discounted drugs for developing countries
1 December 2002. Related: Antiretrovirals.
Hair analysis may help determine drug levels, adherence and virological response
1 December 2002. Related: Antiretrovirals.
Disadvantage from prior nucleoside therapy persists for years during HAART
1 December 2002. Related: Antiretrovirals.
Perspectives on hormonal, mitochondrial and metabolic changes
1 December 2002. Related: Side effects, Lipodystrophy and metabolic complications.
IAS panel issues first guidelines for HIV and HIV drug-related metabolic complications (2002)
1 December 2002. Related: Side effects, Lipodystrophy and metabolic complications.
Side effects are a common cause of intentional non adherence to HAART
1 December 2002. Related: Side effects.
PML-associated immune restoration disease associated with mortality
1 December 2002. Related: Coinfections and complications.
Animal retroviral infections suggest third kind of potential treatment: HIV harm reduction
1 December 2002. Related: Basic science and immunology, Virology.
Memory T cells do not recognise circulating HIV in late infection
1 December 2002. Related: Basic science and immunology.
Chiron halts major IL-2 study, for business reasons
1 December 2002. Related: Other news.
EU increases powers, and speeds up actions, of the European medicines agency
1 December 2002. Related: Other news.
Zinc treatment for diarrhoea reduces child deaths
1 December 2002. Related: Other news.
Post-meeting coverage of the 42nd ICAAC
1 December 2002. Related: On the web.
AIDS-related malignancies in the era of HAART
1 December 2002. Related: On the web.
Screening for and treatment of anal intraepithelial neoplasia
1 December 2002. Related: On the web.
Coping with lipodystrophy’s emotional toll
1 December 2002. Related: On the web.
Beyond HAART: a closer look at immune therapies
1 December 2002. Related: On the web.
Digging deeper at the resistance workshop
1 December 2002. Related: On the web.
Medscape conference coverage
1 December 2002. Related: On the web.
Anaemia, neutropenia, and thrombocytopenia: pathogenesis and evolving treatment options in HIV-infected patients
1 December 2002. Related: On the web.
Comprehensive health care for people infected with HIV in developing countries BMJ 2002;325:954-957
1 December 2002. Related: On the web.
Anti-R7V antibodies may protect some HIV-infected patients from developing AIDS: a conversation with Jean-Claude Chermann
1 December 2002. Related: On the web.
Combining saquinavir with lopinavir/ritonavir?
1 December 2002. Related: On the web.
Glossary of HIV/AIDS-Related Terms, 4th ed
1 December 2002. Related: On the web.
HIV and Its Treatment: What You Should Know, 2nd edition
1 December 2002. Related: On the web.
Volume 3 Number 10 December 2002 PDF
1 December 2002. Related: PDFs.
Profiteers undermine preferential pricing and make millions diverting cheap drugs sent to Africa
13 November 2002. Related: Treatment access.
Activists win court battle in campaign for generic production of ddI
13 November 2002. Related: Treatment access.
Global AIDS fund facing bankruptcy
13 November 2002. Related: Treatment access.
42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, 27-30 September 2002
13 November 2002. Related: Conference reports.
Immunology and treatment interruption data presented at the 42nd ICAAC
13 November 2002. Related: Conference reports, Treatment strategies.
Treatment interruptions may result in poor T-cell recovery in patients with nadir CD+ count <50 cells/mm3
13 November 2002. Related: Conference reports, Treatment strategies.
Treatment interruptions are safe in patients with CD4+ count between 300 to 500 cells/mm3 and viral loads lower than 70,000 copies/mL
13 November 2002. Related: Conference reports, Treatment strategies.
Topical transdermal testosterone gel offers significant clinical benefits in hypogonadal HIV-positive patients
13 November 2002. Related: Conference reports, Other news.
BMS experimental PI atazanavir shows potency comparable to NNRTI efavirenz among treatment-naïve HIV patients
13 November 2002. Related: Conference reports, Antiretrovirals.
Adverse drug reactions and lipodystrophy in children
13 November 2002. Related: Conference reports, Paediatric care, Side effects.
Study suggests Kaletra/Combivir is better tolerated PEP than Combivir/nelfinavir
13 November 2002. Related: Conference reports.
Novel approaches to the inhibition of HIV
13 November 2002. Related: Conference reports.
Lipodystrophy and adverse drug reaction data presented at the 42nd ICAAC
13 November 2002. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
4th International Workshop on Drug Reactions and Lipodystrophy in HIV Infection, San Diego, 22-25 September 2002
13 November 2002. Related: Conference reports.
Leptin, lipodystrophy and insulin resistance
13 November 2002. Related: Conference reports.
A range of treatments for facial lipoatrophy
13 November 2002. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Autopsy evidence confirms that ARVs tackle CNS lesions
13 November 2002. Related: Conference reports, Basic science and immunology.
New evidence favours routine measurement of plasma concentrations in salvage therapy to maintain sustained drug levels
13 November 2002. Related: Antiretrovirals.
New safety information for ddI used with ribavirin
13 November 2002. Related: Treatment alerts, Antiretrovirals.
US FDA issues new safety information for tenofovir co-administration with ddI
13 November 2002. Related: Treatment alerts, Antiretrovirals.
European Commission approves new boosted saquinavir regimen (1000 mg saquinavir/100 mg ritonavir twice daily) for the treatment of HIV-1
13 November 2002. Related: Antiretrovirals.
Tamoxifen for male breast enlargement?
13 November 2002. Related: Side effects, Lipodystrophy and metabolic complications.
Diet can help reduce lipid levels in people with HAART-related dyslipemia
13 November 2002. Related: Side effects, Lipodystrophy and metabolic complications.
HAART enhances regression of cervical intraepithelial neoplasia in HIV-seropositive women
13 November 2002. Related: Women's health, Cancer and HIV.
Study shows why some immune systems can control HIV through CD8 cells
13 November 2002. Related: Basic science and immunology.
Intestinal worm eradication lowers viral load in HIV-positive patients
13 November 2002. Related: Coinfections and complications.
PPAR agonists inhibit HIV replication and TNF-alpha production
13 November 2002. Related: Basic science and immunology.
Many HIV-infected CD4 cells are HIV-specific in patients on HAART
13 November 2002. Related: Basic science and immunology.
Milk thistle can reduce levels of indinavir in the blood
13 November 2002. Related: PK and drug interactions.
The Children’s HIV Association of the UK and Ireland – CHIVA
13 November 2002. Related: Other news.
Highlights of the autumn CHIVA meeting
13 November 2002. Related: Other news.
Multivitamins limit HIV transmission through breastfeeding for some women
13 November 2002. Related: Other news.
Prison health services will be taken over by the NHS from next year
13 November 2002. Related: Other news.
Diagnosis and management of hepatitis C
13 November 2002. Related: On the web.
HIV-1-associated dementia: a basic science and clinical perspective
13 November 2002. Related: On the web.
Clinicians debate antiretroviral tactics and toxicities, resistance testing, and hepatitis virus coinfection
13 November 2002. Related: On the web.